Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

Dick De Zeeuw, Tadao Akizawa, Paul Audhya, George L. Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J. Lambers Heerspink, John J. McMurray, Colin J. Meyer, Hans Henrik Parving, Giuseppe Remuzzi, Robert D. Toto, Nosratola D. Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M. Chertow

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to

Original languageEnglish
Pages (from-to)2492-2503
Number of pages12
JournalNew England Journal of Medicine
Volume369
Issue number26
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease'. Together they form a unique fingerprint.

Cite this